

# Benefits of an Anti-Relapse Gel-Cream Intended for Very Dry, Irritated to Atopic Sensitive Skin: Results From Clinical Study in Babies, Children and Teenagers in India and Argentina

P0131

Helena Polena<sup>1</sup>, Shantal Valdes<sup>2</sup>, Benoît Cadars<sup>1</sup>, Paola Stefano<sup>2</sup>, Elodie Prestat-Marquis<sup>1</sup>

<sup>1</sup> NAOS (BIODERMA), Aix-en-Provence, France, <sup>2</sup> CIREC LATAM, Ciudad Autonoma de Buenos Aires, Argentina

## INTRODUCTION

**Atopic Dermatitis (AD)** is a chronic, relapsing inflammatory dermatosis related to an altered skin barrier, characterized by eczematous flares, xerosis, and pruritus. Affecting 10 – 25 % of children in industrialized countries,<sup>1</sup> it significantly impairs family quality of life, thereby justifying the integration of adapted dermocosmetic strategies providing intensive **anti-pruritic and lipid-replenishing effects**. The objective of this clinical study was to evaluate the **effectiveness** and **tolerance** of an emollient with active ingredients in a **light gel-cream texture** to prevent recurrent acute flares of eczema in patients with AD in **warm and humid environments**.

## MATERIALS & METHODS

This **intra-individual** and prospective study was conducted in **Argentina** and **India** under **dermatological control**. 46 subjects (4 subjects *lost to follow-up*) were included, aged 6 months to 15 years, with **moderate AD and active eruptions**. Subjects received topical treatment (corticosteroids) at inclusion (D0) and had to apply the investigational light gel-cream over their entire body for **120 days**, using standardized "3-6-9" method, adjusted for age and body surface area. Several assessments were performed at baseline (D0) and during follow-up visits (D30, D60, D120) including:

### Clinical assessment

- Eczema Area and Severity Index (EASI)
- Investigator Global Assessment (IGA)
- Relapses

### Biometrological assessment

- Stratum Corneum (SC) Hydration
- Transepidermal water loss (TEWL)

### Subjective Assessments

- Itching, Insomnia
- Quality of Life
- Efficacy


### Dermatological Tolerance

## RESULTS


### Clinical assessment

After 120 days of study product application (with 10.5 days of topical corticosteroids treatment in average at the beginning), **IGA** showed a significant improvement in **AD severity**. The mean **EASI** decreased by **-83.3%** (D120 vs. D0,  $p < 0.001$ , Wilcoxon signed rank-test) and **IGA** decreased by **-77.9%** (D120 vs. D0,  $p < 0.001$ , Wilcoxon signed rank-test):

Graph 1: Evolution of EASI




Graph 2: Evolution of IGA



The mean **number of relapses** was also reduced by **-89.2%** ( $p < 0.001$ , Wilcoxon signed rank-test) comparing the 4 months of the study with the four months prior to it.

### Biometrological assessment (realized outside flare-up areas)


Graph 3: Evolution of SC Hydration



#### Stratum Corneum Hydration

Increase of **22.36%** (D120 vs. D0,  $p < 0.001$ , Wilcoxon signed rank-test)

Graph 4: Evolution of TEWL



#### Transepidermal Water Loss

Decrease of **-20.51%** (D120 vs. D0,  $p < 0.001$ , Wilcoxon signed rank-test)

### Dermatological tolerance

The product was **very well tolerated** by the subjects with no adverse event reported.


## CONCLUSION

This study indicates that the investigational gel-cream texture emollient is **very well tolerated** and is **clinically effective in alleviating AD signs** among **infants, children and teenagers**, in hot and humid regions. Notable improvements were observed across clinical indicators, patient-reported symptoms, skin barrier integrity, and overall quality of life, along with a marked decrease in relapse frequency. The product's favorable tolerability profile and its high satisfaction rates suggest its appropriateness for daily application in **warm environments**, supporting its position as a reliable option for sustained AD management.

<sup>1</sup>Bylund, S.; von Kobyletzki, L. B.; Svalstedt, M.; Svensson, Å. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. *Acta Derm.-Venereol.* **2020**, *100*, 320–329


### Subjective Assessments

Graph 5: Evolution of Itching and Insomnia scores



Patient-reported outcomes also improved significantly, with a **-70.5%** reduction in **Itching** score and an **-83.6%** reduction in **Insomnia** score (D120 vs. D0,  $p < 0.001$ , Wilcoxon signed rank-test).

Graph 6: Evolution of Quality of Life



Quality of life scores decreased significantly:

- For **infants**, regarding the Infants' Dermatitis Quality of Life Index (**IDQOL**) reduction of **-61.9%**, D120 vs. D0 ( $p < 0.05$ , Wilcoxon signed rank-test)
- For **children**, regarding the Children's Dermatitis Life Quality Index (**CDLQI**) reduction of **-82.5%**, D120 vs. D0 ( $p < 0.001$ , Wilcoxon signed rank-test)
- For **families**, regarding the Family Dermatology Life Quality Index (**FDLQI**) reduction of **-72.9%**, D120 vs. D0 ( $p < 0.001$ , Wilcoxon signed rank-test)

As for **teenagers**, the changes concerning the Teenager' Quality of Life (**TQOL**) were considered as not significant, likely due to a small sample size.

### Subjective efficacy

The product effectiveness was rated very positively, with between **97.6% to 100%** of the subjects reporting benefits across all evaluated parameters.